Who should not take Cagrilintide?
Documented caution flags for Cagrilintide include history of medullary thyroid carcinoma or MEN-2 and pancreatitis history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Cagrilintide is limited.
Documented caution flags for Cagrilintide
- History of medullary thyroid carcinoma or MEN-2
- Pancreatitis history
- Pregnancy / nursing
Reported side effects to weigh
- Mild nausea
- Reduced appetite
- Constipation
- Fatigue
References
- Once-weekly cagrilintide for weight management, Phase 2 trial — Lau DCW et al., Lancet, 2021
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — Garvey et al., N Engl J Med, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial — Enebo et al., Lancet, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Cagrilintide
Full Cagrilintide breakdownCagrilintide what it's used forCagrilintide side effectsCagrilintide how to take itCagrilintide mistakes to avoidCagrilintide half-lifeCagrilintide how long to workCagrilintide legal statusCagrilintide how it workscagrilintide vs retatrutidesemaglutide vs cagrilintidetirzepatide vs cagrilintideAsk the AI Coach
Last updated 2026-06-15.